Session Overview The FDA’s Risk Evaluation and Mitigation Strategy (REMS) for mifepristone allows patients to obtain the drug without an in-person visit to a clinician. Ongoing federal litigation has challenged the FDA’s REMS for mifepristone, seeking to add or remove restrictions. In the meantime, mifepristone access is being undermined by additional restrictions at the state...
The road ahead is filled with uncertainty, fear and many challenges, especially for those most marginalized and most vulnerable among us. However, Doctors for America advocates have fought these battles before, and with your help, arm and arm, we will do it again! DFA invites you to join an ALL DFA Advocate Call as we discuss A Path...